Areum Seo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Areum Seo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dohyun Han
Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea
2 shared publications - Dong Ki Kim
Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
2 shared publications - Eunjeong Kang
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications - Eunjin Bae
Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon 51472, Republic of Korea
2 shared publications - Hoe-Yune Jung
R&D Center, NovMetaPharma Co., Ltd., Pohang 37668, Republic of Korea
2 shared publications - Jae Wook Lee
Nephrology Clinic, National Cancer Center Goyang Korea
2 shared publications
Latest Publications
- 15 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13)
Cover Image
- Open Access
- 10 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23819
Protective effect of Cyclo(His‐Pro) on peritoneal fibrosis through regulation of HDAC3 expression
Peritoneal dialysis is a common treatment for end‐stage renal disease, but complications often force its discontinuation. Preventive treatments for peritoneal inflammation and fibrosis are currently lacking. Cyclo(His‐Pro) (CHP), a naturally occurring cyclic dipeptide, has demonstrated protective effects in various fibrotic diseases, yet its potential role in peritoneal fibrosis (PF) remains uncertain. In a mouse model of induced PF, CHP was administered, and quantitative proteomic analysis using liquid chromatography–tandem mass spectrometry was employed to identify PF‐related protein signaling pathways. The results were further validated using human primary cultured mesothelial cells. This analysis revealed the involvement of histone deacetylase 3 (HDAC3) in the PF signaling pathway. CHP administration effectively mitigated PF in both peritoneal tissue and human primary cultured mesothelial cells, concurrently regulating fibrosis‐related markers and HDAC3 expression. Moreover, CHP enhanced the expression of nuclear factor erythroid 2‐related factor 2 (Nrf2) while suppressing forkhead box protein M1 (FOXM1), known to inhibit Nrf2 transcription through its interaction with HDAC3. CHP also displayed an impact on spleen myeloid‐derived suppressor cells, suggesting an immunomodulatory effect. Notably, CHP improved mitochondrial function in peritoneal tissue, resulting in increased mitochondrial membrane potential and adenosine triphosphate production. This study suggests that CHP can significantly prevent PF in peritoneal dialysis patients by modulating HDAC3 expression and associated signaling pathways, reducing fibrosis and inflammation markers, and improving mitochondrial function.
- 10 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23819
Open AccessProtective effect of Cyclo(His‐Pro) on peritoneal fibrosis through regulation of HDAC3 expression
Peritoneal dialysis is a common treatment for end‐stage renal disease, but complications often force its discontinuation. Preventive treatments for peritoneal inflammation and fibrosis are currently lacking. Cyclo(His‐Pro) (CHP), a naturally occurring cyclic dipeptide, has demonstrated protective effects in various fibrotic diseases, yet its potential role in peritoneal fibrosis (PF) remains uncertain. In a mouse model of induced PF, CHP was administered, and quantitative proteomic analysis using liquid chromatography–tandem mass spectrometry was employed to identify PF‐related protein signaling pathways. The results were further validated using human primary cultured mesothelial cells. This analysis revealed the involvement of histone deacetylase 3 (HDAC3) in the PF signaling pathway. CHP administration effectively mitigated PF in both peritoneal tissue and human primary cultured mesothelial cells, concurrently regulating fibrosis‐related markers and HDAC3 expression. Moreover, CHP enhanced the expression of nuclear factor erythroid 2‐related factor 2 (Nrf2) while suppressing forkhead box protein M1 (FOXM1), known to inhibit Nrf2 transcription through its interaction with HDAC3. CHP also displayed an impact on spleen myeloid‐derived suppressor cells, suggesting an immunomodulatory effect. Notably, CHP improved mitochondrial function in peritoneal tissue, resulting in increased mitochondrial membrane potential and adenosine triphosphate production. This study suggests that CHP can significantly prevent PF in peritoneal dialysis patients by modulating HDAC3 expression and associated signaling pathways, reducing fibrosis and inflammation markers, and improving mitochondrial function.